A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
RaDaR™ Residual Disease and Recurrence
The RaDaR™ assay is built on Inivata’s proven InVision® liquid biopsy platform technology. This next-generation sequencing platform incorporates built-in controls and error-correction for highly sensitive and specific variant detection.
RaDaR™ is a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, allowing both detection of residual disease following curative intent or definitive treatment and early detection of relapse.
Initial applications for RaDaR™ will be in clinical research. The availability of an assay with a level of sensitivity that exceeds current fixed panel approaches will allow accurate patient selection for enriched clinical trial populations. This specific patient selection approach may allow for more focused clinical trials with faster recruitment rates. In addition, the ability to track therapeutic treatment success through accurate liquid biopsy will allow earlier visibility of drug efficacy.
Contact us to find out more.